Cannabis NAVIGATING OPPORTUNITIES IN AN OPENING MARKET - DLA Piper
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Cannabis NAVIGATING OPPORTUNITIES IN AN OPENING MARKET
CANNABIS
Introduction
Cannabis remains a controlled substance in
most jurisdictions, but the demand for medicinal,
wellbeing and recreational cannabis products and their
derivatives is undeniable.
The transformative potential of what is emerging,
as governments consider the public health and tax
benefits, reaches far beyond the simple growing and
selling of the plant, as cannabis promises to upend
the status quo in a number of industries.
Entrenched players in the food DLA Piper’s team covers the range
and drink, energy, tobacco and of corporate, intellectual property,
pharmaceutical sectors are all trying technology and R&D, employment,
to anticipate this growing market. regulatory (importantly, both life
Now executives across industries sciences and financial) and litigation
as diverse as cosmetics and pet services, and we are acting across
food are considering how cannabis every segment of pharmaceutical,
is going to reshape their markets, biopharmaceutical, wellness and
and if they should acquire, partner medical sectors around the globe.
or compete with these new entrants. The practice’s provision of legal
services is limited to those clients
One thing is clear, they cannot whose conduct is legal in the
be ignored and this industry is jurisdiction in question.
primed for growth.
High-growth industries with the
DLA Piper is a leading participant breadth and scope of where
in the nascent cannabis industry; cannabis can pervade come with
from start-up to private and an enormous regulatory burden.
public fundraisings, acquisition Smart firms must have a realistic
and post-merger, we are there to plan to deal with the compliance
advise and help clients navigate dragnet that inevitably follows
uncertain waters. We have from a lack of geographical
observed a number of divergent harmonisation. Smarter firms scan
streams materialising from the the horizon and plan ahead of it
shifting tectonic plates of cannabis and that’s where DLA Piper can help.
regulation across the globe.
Uncertainty and service gaps
are appearing as the forces of
innovation and disruption clash
with the variant maturity speeds
of global regimes.
2
WWW.DLAPIPER.COM
3
CANNABIS
Sources of funding for research and
development of cannabis products
capital investment or intellectual
Due to the heavy regulatory burden and criminal
property commercialisation vehicles
categorization of cannabis in a number of countries, and joint ventures, through to other
sources of funding, including further
research on cannabinoids and their therapeutic
rounds of private investment or on
benefits has been limited to date. the public capital markets.
Change is on the horizon, base on the therapeutic benefit Small to medium-sized companies
as governments around the world of these products so that we in particular may not have sufficient
seek to liberalise their laws and can maximize their potential as funds to break into the market
regulations as it relates to cannabis, medicines”. Such research and which can be capital intensive,
in order to encourage, amongst product development will no doubt such as covering the costs of
other things, more R&D in the require significant funding. the regulatory and licensing
sector. For example, research requirements for the sector,
and development in the UK of Companies seeking to develop or or developing their business.
cannabis-based products is sell cannabis products will need They may wish to seek investment
expected to increase significantly to consider how they will fund from private, corporate or
following the UK government’s their businesses. Depending on the institutional investors or look to
recent announcement. In the development stage of the product, raise capital by way of an initial
announcement, the Secretary this can either be through initial public offering (IPO) of equity
of State for Health recognised the funding by university research shares on public markets.
need to “build a greater research grants and spin-outs, venture
4
WWW.DLAPIPER.COM
Venture capital and private equity
• Our experience – more than
We are a market leader in nurturing emerging growth
3,000 venture capital transactions,
companies, seeking access to venture and private totalling over USD40 billion
in value since 2006. We are
equity growth capital, with 600 lawyers around the
consistently ranked among the
world who specifically serve entrepreneurs, start-up top five law firms for global
venture capital, private equity and
companies, funds and other stakeholders. With more
M&A by deal volume
than 95 offices globally, we are strategically positioned (PitchBook, 2006–2018).
to effectively advise and represent investors,
CASE STUDY
licenced producers, licenced dealers, laboratories, Acreage Holdings
We acted for Acreage Holdings, a
pharmaceutical companies, service providers,
leading U.S. multi-state cannabis
start-ups and established businesses on a full range of operator on its USD3.4 billion
arrangement with Canopy
legal issues relating to the cannabis industry where it is
Growth. Canopy Growth received
lawful to do so. the option to acquire all of the
issued and outstanding shares in
Growing your business Why choose us the capital of Acreage Holdings,
For today’s emerging growth Emerging growth clients need with a requirement to do so,
company to become tomorrow’s more than just advice to help upon a change in United States
success story, an organisation their businesses prosper. federal laws to permit the
must be prepared to face a host They need a legal services provider general cultivation, distribution
of challenges, and few industries committed to serving companies and possession of marijuana.
present more complex legal issues at all stages of the corporate life
than the fledgling cannabis industry. cycle, from start-up to mature • Our focus – the attentiveness and
From protecting intellectual property business. We offer a combination responsiveness of locally qualified
and technology to selecting the right of capabilities that enable us to lawyers, combined with the
management team, many decisions position companies for success relationships and resources that
can have an immediate impact on the including: only a global law firm can offer.
fortunes of a company.
• Our approach and business
And the margin for error can be • Our relationships – a network
insight – practical insights to
slight in the intensely competitive of established relationships
develop entrepreneurs into
marketplace and regulatory with angel, venture, institutional
leaders of successful businesses,
environment. The stakes become and strategic investors within
including advice concerning
higher as companies look to trade the venture capital and private
business problems they
across borders. equity community.
should anticipate and how to
• Our unmatched network – overcome them.
Our emerging growth and venture
throughout Africa, Asia-Pacific,
capital group understands
Europe, the Middle East, Canada
this environment. Our clients
and the United States,
compete in high-profile areas
we are one of the few firms
like high tech, insurtech, fintech
with an established corporate
and biotech, and now, cannabis.
practice that can effectively
We assist emerging companies at
represent venture capitalists and
all stages of development, with a
private equity houses investing
commitment to helping them build
abroad and emerging companies
sustainable businesses.
“going global”.
5
CANNABIS
Growth, strategy and legal advice –
how we can help
Business growth and information, defining objectives cannabis comes advancements in
exit strategy planning of the transaction, identifying and technology in adjacent markets,
As companies leave the “seed” reconciling competing interests as the market matures.
stage and begin to explore and and driving parties toward mutually
test avenues for growth, their beneficial agreements. Comprehensive legal
needs change and become more counsel to emerging
sophisticated. We help them Intellectual property companies
evaluate and prepare expansion and technology We are a full service law firm in every
strategies, including partnerships development, jurisdiction we operate. We counsel
and joint ventures, mergers and exploitation and companies in areas critical to both
acquisitions and, if appropriate, protection their short-term and ongoing
public equity investment. Our IP services are particularly success, including the following:
important to companies that need domestic and international tax,
Innovative business to harness, protect and exploit the corporate, employment, finance,
arrangements, including technologies behind their products intellectual property and technology,
corporate partnering and services to realise their international trade and transfer
and strategic alliances objectives. For example, we provide pricing, regulatory and government
Our lawyers help clients IP advice to leading innovators in affairs, litigation, arbitration and
formulate research and fast-growing industries such as investigations, projects, energy
development agreements, life sciences, IT, digital media and and infrastructure, real estate
applying our experience in wireless communications. With and restructuring.
evaluating complex technical new innovations surrounding legal
6
WWW.DLAPIPER.COM
IPO opportunities –
which market to choose
Companies looking to raise equity • how to ensure compliance with the equity and debt capital raising
are not only presented with regulatory regime (including having transactions. We have built a strong
the potential of private capital, the required licences, certificates global platform based on deep
but increasingly medicinal cannabis and approvals); industry knowledge in key growth
companies have sought to raise sectors, including in the medicinal
• how to ensure they are adequately
equity via the public markets. cannabis industry, and access to
protected against participating in
The increased profile provided by an global funding sources through
the proceeds of crime;
initial public offering (IPO) presents relationships with the business and
an opportunity to transform a • how to ensure they have adequate funding communities, including
company’s profile. The Toronto brand and intellectual property investment banks, private equity
Stock Exchange, the TSX Venture protection; and venture capital providers and
Exchange and Canadian Securities hedge funds.
• how much money is required to be
Exchange have been early movers
raised; and
in providing a platform for investors
to access companies with global • which market(s) to seek admission CASE STUDY
ambitions. Elsewhere companies are to trading on. We acted for leading hemp/
eager to understand their ability to CBD company, Charlotte’s Web
At DLA Piper, we offer integrated
raise capital on the NASDAQ or the Holdings, Inc. in connection with
securities advice on complex
NYSE in the US, the ASX in Australia their CAD$115 million Initial
cross-border transactions to
and on the NEX, LSE’s Main Market, Public Offering and Secondary
companies as issuers, their key
AIM or the Frankfurt Stock Exchange Offering and listing on the
stakeholders and management,
in Europe. As countries around the Canadian Securities Exchange
underwriters, sponsors, and lead
world liberalise regulation in relation in August of 2018. Nine months
managers on IPOs and a broad range
to cannabis, the opportunity to later in May of 2019,
of other securities offerings and any
raise public capital is an attractive after approval of the Farm Bill
associated market compliance.
prospect in an industry that in the United States, we advised
demands significant capital. the company again on their
Companies, underwriters and
uplisting to the Toronto Stock
placement agents rely on us to
There are a number of factors Exchange, increasing their
deliver global advice and unmatched
that cannabis companies who profile and a reflection of the
local, on-the-ground resources
are looking to raise money will company’s continued growth.
to support public and private
need to consider, including:
7
CANNABIS
Operating in the regulated
cannabis sector
The legal issues and considerations for businesses operating in the cannabis sector
will vary depending on which aspect(s) of the production cycle they operate within.
The following is therefore only a brief summary of some of the issues and
considerations in this nascent market:
• At each stage in the supply made through the illegal drugs • Companies will need to ensure
chain (e.g. supply, cultivation), trade, or indeed holding/ the products being supplied by
manufacture and distribution, transferring illegal cannabis them (if applicable) meet any
companies will need to ensure itself or indirectly participating minimum required standards
they have all of the necessary in the sale of recreational for products of that type.
certificates, licences and cannabis in jurisdictions where They should also ensure the
approvals. Companies should it is unlawful. For example, a products meet their own internal
ensure they have these in place as company processing cannabis standards or market expectations,
early as possible. leaf or manufacturing the which may be higher than the
medicine needs to be certain of regulatory minimum.
• Recreational cannabis is
the provenance of its supply and
still and will continue to be • Linked to the above, they should
disposal of its by products.
illegal across a number of also consider whether they
jurisdictions. Companies will • Labelling and packaging need relevant quality control
need to ensure that they have requirements will need to be certification such as EU-GMP and
adequate protections in place complied with at each stage engage appropriate consultants
to prevent them incurring any in the production cycle, as will and lawyers to advise.
liability under, for example, health and safety requirements
• Companies holding or
the UK’s Proceeds of Crime Act (particularly relating to the
distributing cannabis seeds,
2002, or its drugs legislation. handling and storage of
cannabis plants or cannabis-
They will need to be certain cannabis or cannabis-related
based products will need to
that they are not receiving/ products where applicable).
ensure they have adequate
transferring proceeds of crime
8
WWW.DLAPIPER.COM
security and stock control • Brand protection will be
RECREATIONAL USE
protections in place to ensure important, particularly
Use of cannabis in the UK will still
that supplies are secure and for companies involved in
be strictly limited to medicinal
accounted for at all times. developing and marketing new
purposes on prescription from
cannabis-derived medicinal
• Companies involved in a specialist doctor (excluding
and wellness products to
the distribution of either CBD-derived products). This
hospitals/pharmacies and health
cannabis or cannabis-derived is limited to activity with the
food stores.
products will need to ensure definition of cannabis-based
they comply with all laws • If a company is developing its products for medicinal use.
regarding distribution and good own cannabis-based medicines, In its announcement on
manufacturing processes. it should also consider how to 21 September 2018, the UK
protect its intellectual property. government made it clear that
• If a company is renting
it does not intend to legalize
premises, it will need to ensure • Relaxation of the drug laws
the recreational use
that its lease does not prohibit globally to allow the medicinal use
of cannabis.
it from carrying out its work in of cannabis is an emotive issue
relation to medicinal cannabis, which attracts strong opinions
e.g. manufacturing or research. on both sides. Companies will
Even if the company owns therefore need to consider that
its premises, it will need to they may need to deal with
ensure its proposed use of the negative press and should ensure
site is permitted use from their security arrangements
a planning perspective. are sufficient to deal with
potential hostility.
9
CANNABIS
Relevant cannabis experience
A regulated cannabis market could create significant business opportunities and
Europe is seen as a key source of funding for medicinal cannabis developers.
Both domestic European companies and established companies from countries
such as Canada are expected to come to major European financial centres to raise
capital and grow their businesses.
Canada is the acknowledged leader in the cannabis sector and it is expected to lead
globally in this industry.
OUR RECENT EXPERIENCE INCLUDES ADVISING:
• Acreage Holdings (CSE: ACRG.U) on its USD3.4 billion • CannTrust Holdings’ (TSX: TRST) CAD100 million
arrangement with Canopy Growth. bought deal offering of units.
• Acreage Holdings on its USD428 million financing • Golden Leaf Holdings’ CAD15 million bought deal
and reverse takeover and CSE listing (CSE: ACRG.U). private placement.
• Advising ASX listed medicinal cannabis company, • MedReleaf’s CAD132.5 million bought deal offering
Althea Group Holdings Ltd (ASX: AGH), on its of units.
acquisition of Canadian extraction and contract
• Canaccord Genuity, in connection with Aurora
manufacturing company Peak Processing Solutions,
Cannabis’ (TSX: ACB) USD115 million special
together with Althea’s associated AUD30 million
warrant offering.
capital raising.
• Canaccord Genuity, in connection with Golden
• Advising an American multinational
Leaf Holdings’ (CSE: GLH) USD20.4 million secured
biopharmaceutical company on trademark
convertible debenture offering.
clearances and filings in China, Hong Kong and Macau
for new products. • Canaccord Genuity, as lead underwriter, on a private
placement for Canaccord Genuity Growth, a special
• An Australian medicinal cannabis company in
purpose acquisition corporation, in connection with
relation to its development and construction of a
its proposed acquisition of Columbia Care.
cannabis growing and processing facility.
• A syndicate of underwriters, led by Canaccord
• A boutique retail chain on its own brand CBD
Genuity, in connection with a USD40.3 million bought
cosmetic line and the legality of its products and their
deal private placement of Supreme Pharmaceuticals
provenance across Italy, UK, Switzerland and France.
Inc.’s (TSXV: FIRE) convertible debentures.
• A syndicate of agents led by Canaccord Genuity, in
• A syndicate of underwriters, co-led by Canaccord
connection with:
Genuity and Eight Capital, in connection with
• Aurora Cannabis’ (TSX: ACB) USD230 million ABcann Global’s (TSXV: ABCN) USD70 million bought
bought deal offering of convertible debentures. deal offering of units and convertible debentures.
• CannaRoyalty’s USD32.9 million offering of
unsecured convertible debentures.
10WWW.DLAPIPER.COM
• A syndicate of agents, led by Canaccord Genuity and • Charlotte’s Web Holdings (CSE: CWEB) on its
PowerOne Capital Markets and including Gravitas USD110 million IPO and CSE listing.
Securities in connection with a Sante Veritas
• China AgroTech Holdings Limited on the acquisition
Therapeutics USD20 million offering.
by China Agrotech Holdings Limited, a company listed
• A syndicate of underwriters, led by Canaccord on the Main Board of the Hong Kong Stock Exchange,
Genuity and including Beacon Securities, Cormark of a company engaged in the planting and sales of
Securities, Eight Capital, GMP Securities and PI landscaping seedlings in PRC, with a deal value of
Financial, in connection with a USD40.3 million USD129 million.
bought deal private placement of Supreme
• Representing one of the largest Chinese
Pharmaceuticals (TSXV: FIRE) convertible debentures.
biotechnology CMOs/CROs in multiple cross-border
• A syndicate of underwriters, led by Canaccord transactions, including an in-license of DNA library
Genuity and including GMP Securities, PI Financial, screening technology from a top U.S. university and a
Eight Capital, Industrial Alliance Securities, joint development and collaboration agreement with
Beacon Securities and Mackie Research Capital, a U.S. supplier of API compounds.
in connection with Aurora Cannabis (TSX: ACB)
• A syndicate of dealers co-led by Cormark Securities
USD75 million bought deal and concurrent private
and Canaccord Genuity in connection with
placement.
Growforce Holdings’ USD38 million subscription
• A syndicate of agents, led by Canaccord Genuity receipt offering.
and including Industrial Alliance Securities, Mackie
• A developer of a medicinal cannabis delivery
Research Capital and Sprott Capital, in connection
device in relation to the regulatory requirements
with Maricann Group (CSE: MARI) USD31 million
of the Australian market, as well as in relation to
secured convertible debenture offering.
corporate and tax issues.
• A syndicate of agents, co-led by Canaccord Genuity
• The Flowr Corporation on trade mark portfolio
and GMP Securities in connection with Maricann
management, trade mark searching and clearance,
Group’s USD37.4 million special warrant offering.
trade mark prosecutions and related brand
• A syndicate of agents, including Canaccord Genuity enforcement in the Asia-Pacific region.
and PI Financial, in connection with ABcann Global’s
• A global payment services provider on the legal
(TSXV: ABCN) USD15 million convertible debenture
framework for the sale and import of cannabis
financing, reverse take over and TSX Venture
derived products in over 15 jurisdictions in Europe.
Exchange listing.
11CANNABIS
• Hanway Associates, a London-based cannabis • Advising Soma Group Limited, a medical research
consultancy on all their legal matters, corporate and health foods company, in connection with its seed
strategy and expansion plans. capital raise.
• Advising Hanway Associates, the cannabis • The Cannabis Company, a developer and supplier
consultancy business, on the disposal of their interest of hemp infused FMG and consumable products for
in HAPP Holdings Limited to NOBL Group. HAPP humans and pets, in relation to venture capital and
Holdings owns the market leading conference series seed investments.
Cannabis Europa.
• Trulieve Cannabis (CSE: TRUL) on its CAD65 million
• HEXO Corp with its dual listing on the NYSE in private placement of subscription receipts, reverse
addition to its TSX listing. take over of Schyan Exploration and CSE listing.
• High Street Capital Partners on its USD314.2 million • Advising Ultra Hemp Extract, on the regulatory
subscription receipt financing, reverse take-over of requirements for importing hemp CBD products
Applied Inventions Management and the listing of the (dietary supplements and/or food products)
resulting issuer, Acreage Holdings (CSE: ACRG.U), on into New Zealand.
the Canadian Securities Exchange.
• A US manufacturer of hemp oil on Australian and
• Advising a Malaysian biotech company in relation to New Zealand regulatory and import requirements
a plantation acquisition in China and in joint venture relating to cannabis products.
negotiations with U.S. multinational companies.
• Assisting a large US pharmaceutical company in
• Materia Ventures on its expansion plans into Europe. relation to a number of internal investigations across
various cities in China.
• Newstrike Brands (TSX-V: HIP) in a share purchase
agreement for interest in Neal Brothers Brands Inc.
We are ready to apply our
and joint venture agreement.
knowledge and experience of
• Ping An Good Doctor as special corporate counsel
in its initial public offering on the Hong Kong Stock the cannabis sector to help
Exchange and pre-IPO restructuring, with the whole
companies, investors and
company valued at USD7.5 billion.
other stakeholders navigate
• A producer of medicinal cannabis and cannabis oils
on the Australian regulatory regime for cannabis and and operate in the UK and
cannabis products, as part of an international project.
European markets.WWW.DLAPIPER.COM
Ranked #1 Ranked #1
Global M&A by deal Global M&A by
volume 2010 – 2019 deal volume 2019
(MERGERMARKET) (THOMSON REUTERS)
Ranked #1 Ranked #1
Worldwide Mid-Market European M&A
and Small-Cap M&A by by deal volume
deal volume 2019 2013 – 2019
(THOMSON REUTERS) (MERGERMARKET)
Ranked #1 Ranked #1
Most active law firm Europe Private
in Europe for private Equity, Buyouts and
equity deals 2019 Exits 2016 – 2019
(PITCHBOOK) (MERGERMARKET)
Ranked #2 #2 Most active law
Most active law firm firm in Europe –
globally for private venture capital
equity deals 2019 deals 2019
(PITCHBOOK) (PITCHBOOK)
Deal of the Year: Law Firm
Global Corporate of the Year
M&A Deal, Transactions
(UNQUOTE PRIVATE EQUITY
Mid-market 2019
AWARDS 2018)
(M&A ATLAS AWARDS)
The only firm to rank as one of the
top five most active law firms for
private equity, venture capital and
M&A deal volume 2019
(PITCHBOOK)
13CANNABIS
Our European team
To learn more about our capabilities in Europe, please contact one of our team
members below.
Marco de Morpurgo Dylan Kennett
Partner/Global Co-Chair (Life Sciences) Senior Associate, Corporate
Intellectual Property & Technology (London)
(Rome) +44 20 7796 6159
+39 06 68 880 520 dylan.kennett@dlapiper.com
marco.demorpurgo@dlapiper.com
Laura Ford Luca Gori
Partner, Litigation & Regulatory Partner, Corporate
(Birmingham) (London)
+44 20 7153 7058 +44 20 7796 6469
laura.ford@dlapiper.com luca.gori@dlapiper.com
Ulrik Bangsbo Hansen Dr Roland Maaß
Partner, Corporate Partner, Corporate
(Copenhagen) (Frankfurt)
+45 33 34 00 08 +49 69 271 33 410
ulrik.bangsbo@dlapiper.com roland.maass@dlapiper.com
Jan Snogdal Robert Salter
Partner, Corporate Partner, Corporate
(Aarhus) (London)
+45 33 34 08 40 +44 20 7153 7542
jan.snogdal@dk.dlapiper.com rob.salter@dlapiper.com
Dr Mathias Schulze Steinen Dr Kokularajah
Partner, Corporate Paheenthararajah
(Frankfurt) Senior Associate, Intellectual
+49 69 271 33 430 Property & Technology (Cologne)
mathias.schulze.steinen@ +49 221 277 277 307
dlapiper.com kokularajah.paheenthararajah@
dlapiper.com
Rahool Sarjua
Guido Kleve
Senior Associate, Intellectual
Partner, Litigation & Regulatory
Property & Technology
(Cologne)
(London)
+49 221 277 277 353
+44 20 7153 7968
guido.kleve@dlapiper.com
rahool.sarjua@dlapiper.com
14WWW.DLAPIPER.COM
Our North American team
To learn more about our capabilities in North America, please contact one of our
team members below.
Russel W. Drew Robert Fonn
Partner, Corporate Partner, Securities & Corporate
(Toronto) Finance (Toronto)
+1 416 369 5260 +1 416 369 5280
russel.drew@dlapiper.com robert.fonn@dlapiper.com
Noam Goodman Robbie Grossman
Partner/Global Co-Chair (Retail) Partner, Corporate
Corporate (Toronto) (Toronto)
+1 416 862 3361 +1 416 369 5265
noam.goodman@dlapiper.com robbie.grossman@dlapiper.com
Sanjay M. Joshi Vaughn MacLellan
Partner, Corporate Partner, Securities & Corporate
(Toronto) Finance (Toronto)
+1 416 369 5287 +1 416 365 3407
sanjay.joshi@dlapiper.com vaughn.maclellan@dlapiper.com
Ted Maduri Derek Sigel
Partner/Co-Chair, Partner, Securities & Corporate
Canadian Corporate Group Finance (Toronto)
(Toronto) +1 416 365 3516
+1 416 941 5412 derek.sigel@dlapiper.com
ted.maduri@dlapiper.com
Trevor Wong-Chor Jarrod Isfeld
Partner/Chair Partner, Securities &
Canadian Securities & Capital Capital Markets
Markets Group (Calgary) +1 403 776 8821
+1 403 698 8711 jarrod.isfeld@dlapiper.com
trevor.wong-chor@dlapiper.com
Sydney Kert Jamie Mandell
Associate, Corporate Associate, Corporate
(Toronto) (Toronto)
+1 416 941 5393 +1 416 862 3353
sydney.kert@dlapiper.com jamie.mandell@dlapiper.com
Nicole Kapos Amy Pressman
Counsel, Corporate Partner, Litigation, Arbitration &
(Toronto) Investigations (Toronto)
+1 416 941 5418 +1 416 369 5293
nicole.kapos@dlapiper.com amy.pressman@dlapiper.com
15CANNABIS
Our North American team cont.
Michael Reid Morgan McDonald
Partner, Corporate (Vancouver) Counsel, Corporate (Vancouver)
+604 643 2933 +604 643 6416
michael.reid@dlapiper.com morgan.mcdonald@dlapiper.com
Camilo Martinez
Managing Partner (Colombia)
+57 1 317 4720
cmartinez@dlapipermb.comWWW.DLAPIPER.COM
Our Asia Pacific team
To learn more about our capabilities in the Asia Pacific, please contact one of
our team members below.
Melinda Upton Chris Mitchell
Partner/Global Co-Chair, Intellectual Partner, Corporate
Property & Technology (Melbourne)
(Sydney) +61 3 9274 5145
+61 2 9286 8209 chris.mitchell@dlapiper.com
melinda.upton@dlapiper.com
Greg Bodulovic Jessie Buchan
Special Counsel, Intellectual Senior Associate, Intellectual
Property & Technology Property & Technology
(Sydney) (Sydney)
+61 2 9286 8218 +61 2 9286 8552
greg.bodulovic@dlapiper.com jessie.buchan@dlapiper.com
William (Skip) Fisher Stewart Wang
Partner, Intellectual Property & Partner, Corporate
Technology (Shanghai)
(Shanghai) +86 21 3852 2080
+86 21 3852 2198 stewart.wang@dlapiper.com
william.fisher@dlapiper.com
Ting Xiao Douglas Mancill
Registered Foreign Lawyer, Senior Consultant, Corporate
Intellectual Property & Technology (Bangkok)
(Shanghai) +6626868559
+86 21 3852 2039 douglas.mancill@dlapiper.com
ting.xiao@dlapiper.com
Sam Wilson
Senior Associate, Corporate
(Auckland)
+64 9 300 3842
sam.wilson@dlapiper.com
17CANNABIS
Our global footprint
DLA Piper presence
Cooperation firm
AMERICAS EUROPE MIDDLE EAST AFRICA ASIA PACIFIC
Albany Philadelphia Aarhus Madrid Abu Dhabi Algiers Auckland
Atlanta Phoenix Amsterdam Manchester Al Khobar Addis Ababa Bangkok
Atlantic City Raleigh Antwerp Milan Doha Accra Beijing
Austin Rio de Janeiro* Birmingham Moscow Dubai Bujumbura Brisbane
Baltimore Sacramento Bratislava Munich Jeddah Casablanca Hong Kong
Bogota San Diego Brussels Oslo Kuwait City Dakar Melbourne
Boston San Francisco Bucharest Paris Manama Dar es Salaam Perth
Buenos Aires San Juan Budapest Prague Muscat Harare Seoul
Calgary Santiago Cologne Rome Riyadh Johannesburg Shanghai
Chicago São Paulo* Copenhagen Sheffield Gaborone Singapore
Dallas Seattle Dublin St. Petersburg Kampala Sydney
Edmonton Short Hills Edinburgh Stockholm Kigali Tokyo
Houston Silicon Valley Frankfurt Vienna Lagos Wellington
Lima Toronto Hamburg Warsaw Luanda
Los Angeles Vancouver Helsinki Lusaka
Mexico City Washington, DC Kyiv Maputo
Miami Wilmington Leeds Mwanza
Minneapolis Yellowknife Lisbon Nairobi
Montreal Liverpool Port Louis
New York London Tunis
Northern Virginia Luxembourg Windhoek
Zanzibar
* Cooperation firms
18WWW.DLAPIPER.COM
19DLA Piper is a global law firm operating through various separate and distinct legal entities. Further details of these entities can be found at www.dlapiper.com. This publication is intended as a general overview and discussion of the subjects dealt with, and does not create a lawyer-client relationship. It is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. DLA Piper will accept no responsibility for any actions taken or not taken on the basis of this publication. This may qualify as “Lawyer Advertising” requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome. Copyright © 2020 DLA Piper. All rights reserved. | FEB20 | A03701
You can also read
